BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
BioVie Inc. (NASDAQ: BIVI) is set to feature in an interview on The RedChip Money Report, airing on Bloomberg TV on September 17, discussing advancements in clinical research. CEO Cuong Do will outline the promising top-line results from a Phase 2 study of NE3107 for Alzheimer's Disease, along with updates on ongoing Phase 3 and Phase 2 trials related to Alzheimer's and Parkinson's diseases, respectively. The company is focusing on addressing unmet medical needs in chronic liver and neurodegenerative disorders, with significant milestones expected soon.
- Positive initial top-line results from Phase 2 study of NE3107 in Alzheimer's Disease.
- Updates on ongoing Phase 3 Alzheimer's and Phase 2 Parkinson's clinical trials.
- FDA Fast Track status for BIV201, targeting refractory ascites due to liver cirrhosis.
- None.
ORLANDO, FL / ACCESSWIRE / September 15, 2022 / RedChip Companies will air a new interview with BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, on The RedChip Money Report® on Bloomberg TV, this Saturday, September 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Interview highlights:
In the exclusive RedChip Money Report interview, BioVie's CEO and President Cuong Do discusses positive initial top-line results from an Investigator-Sponsored Phase 2 exploratory biomarker study for NE3107 in Alzheimer's Disease. Updates on the Company's Phase 3 Alzheimer's and Phase 2 Parkinson's trials, upcoming milestones, and much more are discussed.
Access this interview in its entirety at https://www.biviinfo.com/interview_access
About The RedChip Money Report®
The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2 study for the treatment of refractory ascites due to liver cirrhosis with top-line results anticipated in early 2023. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not available in the U.S. or Japan. In neurodegenerative disease, the Company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF transcription) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer's and Parkinson's diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028). An estimated six million Americans suffer from Alzheimer's. BioVie has initiated this study and is targeting primary completion in mid-2023. A Phase 2 study of NE3107 in Parkinson's disease is enrolling patients and expect to have topline data readout by mid-year 2022. NE3107 is patented in the United States, Australia, Canada, Europe, and South Korea. For more information, visit http://www.bioviepharma.com/.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Contact:
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
BIVI@redchip.com
SOURCE: RedChip
View source version on accesswire.com:
https://www.accesswire.com/716117/BioVie-Inc-Interview-to-Air-on-Bloomberg-US-on-the-RedChip-Money-ReportR
FAQ
What is BioVie Inc.'s stock symbol?
When will BioVie Inc.'s interview air on Bloomberg TV?
What are the key highlights discussed in BioVie Inc.'s interview?
What is the status of BioVie Inc.'s drug candidate BIV201?
What diseases is BioVie Inc. focusing on with their drug candidates?
